Integrated Wealth Management (Palm Desert)’s Esperion Therapeutics ESPR Stock Holding History

Integrated Wealth Management (Palm Desert)’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-200	Closed	-$3K	–	454
2016 Q3	$3K	Hold	200	–	–	﹤0.01%	988
2016 Q2	$2K	Sell	200 -1,200	-86%	-$19.9K	﹤0.01%	1063
2016 Q1	$24K	Hold	1,400	–	–	0.01%	517
2015 Q4	$31K	Hold	1,400	–	–	0.01%	482
2015 Q3	$33K	Buy	1,400 +800	+133%	+$50.2K	0.01%	461
2015 Q2	$49K	Buy	600 +400	+200%	+$39.2K	0.02%	396
2015 Q1	$18K	Buy	+200	New	+$12.9K	0.01%	597

Other funds holding ESPR

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Integrated Wealth Management (Palm Desert)'s ESPR Position: Q4 2016 in Review

Integrated Wealth Management (Palm Desert) sold out of Esperion Therapeutics (ESPR) in Q4 2016, closing a stake of 200 shares — an estimated $3K sold.

Integrated Wealth Management (Palm Desert) first reported a position in ESPR in Q1 2015 and held it in 7 quarters. The position peaked at $49K in Q2 2015. 99 funds tracked by Wall St. Rank hold ESPR as of Q4 2016.

Integrated Wealth Management (Palm Desert) reported no remaining Esperion Therapeutics position as of Q4 2016 after selling out during the quarter.
Integrated Wealth Management (Palm Desert) sold 200 Esperion Therapeutics shares in Q4 2016, an estimated $3K.
Integrated Wealth Management (Palm Desert) first reported a position in Esperion Therapeutics in Q1 2015 and held it in 7 quarters.
Integrated Wealth Management (Palm Desert)'s Esperion Therapeutics position peaked at $49K in Q2 2015.
99 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2016.

Based on Integrated Wealth Management (Palm Desert)'s 13F filing for Q4 2016, filed 6 Jan 2017.